2024 profitability somewhat exceeded expectations; stock re-rating underway
17/03/25 -"Virbac’s 2024 operating profitability was somewhat ahead of the street’s expectations, backed by favourable prices, higher volumes and an improved product mix. Nonetheless, the announced ..."
Pages
59
Language
English
Published on
17/03/25
You may also be interested by these reports :
07/05/25
Q1 profits exceeded the street’s expectations. Nonetheless, 2025 guidance was downgraded owing to competition from compounded drugs, which, however, ...
06/05/25
1:10 share split adjustments – Downgrade to Add (prev.: Buy)
06/05/25
Q1 results met expectations, and strong growth was witnessed across the segments as well as three key molecules. Of note was a rebound in the animal ...
05/05/25
BioNTech’s narrative is straightforward: the company develops drugs for life-threatening illnesses and generated significant revenue by developing ...